• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleotides Purine ribonucleoside diphosphates
• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleotides Purine ribonucleotides Purine ribonucleoside diphosphates

2-Amino-9-{5-o-[hydroxy(phosphonooxy)phosphoryl]pentofuranosyl}-1,9-dihydro-6h-purin-6-one: A Comprehensive Overview

The compound with CAS No. 168035-01-6, commonly referred to as 2-Amino-9-{5-o-[hydroxy(phosphonooxy)phosphoryl]pentofuranosyl}-1,9-dihydro-6h-purin-6-one, is a highly specialized molecule that has garnered significant attention in the fields of organic chemistry and pharmacology. This compound is notable for its complex structure, which includes a purine ring system and a pentofuranosyl group, making it a unique subject of study for researchers exploring nucleoside analogs and their potential applications in drug development.

Purine analogs have long been of interest in medicinal chemistry due to their structural similarity to natural nucleosides, which are essential components of DNA and RNA. The presence of the purin-6-one core in this compound suggests its potential role as a nucleoside analog, which could be exploited in antiviral or anticancer therapies. Recent studies have highlighted the importance of such compounds in targeting viral polymerases and inhibiting their activity, thereby offering a promising avenue for therapeutic intervention.

The pentofuranosyl group attached to the purine ring introduces additional complexity to the molecule. This group is characterized by a five-membered ring structure containing oxygen atoms, which contributes to the compound's hydrophilic properties. The hydroxy(phosphonooxy)phosphoryl substituent further enhances the molecule's functional versatility, potentially enabling interactions with biological systems at multiple levels. This makes the compound an intriguing candidate for exploring its bioavailability and pharmacokinetic properties.

Recent advancements in synthetic chemistry have enabled researchers to synthesize this compound with greater precision and efficiency. Techniques such as microwave-assisted synthesis and enzymatic catalysis have been employed to optimize the production process, ensuring higher yields and better purity. These innovations are critical for scaling up production, which is essential for preclinical and clinical trials.

In terms of pharmacological activity, 2-Amino-9-{5-o-[hydroxy(phosphonooxy)phosphoryl]pentofuranosyl}-1,9-dihydro-6h-purin-6-one has shown promising results in vitro studies. Its ability to inhibit key enzymes involved in viral replication has been extensively documented, making it a potential candidate for antiviral therapies. Additionally, its selectivity towards certain cellular pathways suggests that it may have fewer off-target effects compared to existing drugs.

The amino group present in the molecule plays a crucial role in its biological activity. This functional group not only enhances the molecule's solubility but also facilitates interactions with proteins and enzymes. Recent research has focused on modifying this group to improve the compound's efficacy and reduce potential toxicity. Such modifications are part of ongoing efforts to refine the molecule for therapeutic use.

From an analytical standpoint, modern spectroscopic techniques such as NMR (nuclear magnetic resonance) and MS (mass spectrometry) have been instrumental in confirming the compound's structure and purity. These methods provide detailed insights into the molecule's conformational dynamics and stability under various conditions, which are vital for understanding its behavior in biological systems.

Looking ahead, the development of this compound into a clinically viable drug requires further investigation into its pharmacodynamics and toxicology profiles. Preclinical studies are currently underway to assess its safety and efficacy in animal models. If successful, these studies will pave the way for human trials, bringing us closer to realizing its therapeutic potential.

In conclusion, 2-Amino-9-{5-o-[hydroxy(phosphonooxy)phosphoryl]pentofuranosyl}-1,9-dihydro-6h-purin-6-one represents a significant advancement in nucleoside analog research. Its unique structure and promising pharmacological properties make it a compelling candidate for developing novel therapeutics against viral infections and other diseases. As research continues to unfold, this compound holds great promise for contributing to the advancement of medicinal chemistry and personalized medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)